Search Clinical Trials Search
Clinical Trials
× ...
Sort & Filter
Sort by
Specialty
Disease or Condition
Age Group

Drug/Medication

155 results found

Lung

Checkpoint Blockade in Lung Cancer Patients in the Adjuvant Setting

The purpose of this study is to compare the usual treatment alone (immune-based therapy with medications like durvalumab) to the usual treatment plus an experimental medication, AZD6738 (ceralasertib), in people with lung cancer who have ...

Lung

Incorporating Pathologic Complete Response in Non-Small Cell Lung Cancer to Optimize Immunotherapy

The purpose of this study is to compare the usual approach of observation (closely watching a patient’s condition after surgery) to taking an immunotherapy drug, durvalumab (MEDI4736), in people with early-stage, non-small cell lung cancer ...

Kidney

Alliance, A032201, Ph3, Rand, RCC, Pembrolizumab vs Pembrolizumab + Tivozanib

Primary Objective: 1. To compare disease free survival (DFS) as assessed by the investigator for high-risk renal cell carcinoma patients treated with adjuvant pembrolizumab and tivozanib versus those receiving pembrolizumab alone Secondary Objectives: 1. To compare overall survival ...

Prostate

Merck,MK-2400-001, Ph 3, open label, Prostate Ca, Ifinatamab Deruxtecan Versus Docetaxel

Primary Objective: To compare infinatamab deruxtecan (I-DXd) to docetaxel with respect to overall survival (OS) in participants with mCRPC. To compare I-DXd to docetaxel with respect to radiographic progression-free survival (rPFS) per Prostate Cancer Working ...

Anus, Breast, Lung, Other Female Genital, Ovary, Unknown Sites

Sumitomo Pharma America, Inc, SMP-3124-101, PhI/II, Open-label, SMP-3124LP, Solid tumors

Primary Objective: Dose Escalation: Determine the Recommended Phase 2 Dose (RP2D). Assess the safety and tolerability. Dose Expansion: Evaluate preliminary antitumor activity. Secondary Objectives: Dose Escalation: Establish the plasma PK profile of SMP-3124 and SMP-3124LP. Evaluate ...